Tools
Tools
Li, Vivien, Leurent, Baptiste, Barkof, Frederik, Braisher, Marie, Cafferty, Fay, Ciccarelli, Olga, Eshaghi, Arman, Gray, Emma, Nicholas, Jennifer, Parmar, Max, Peryer, Guy 
ORCID: https://orcid.org/0000-0003-0425-6911, Robertson, Jenny, Stallard, Nigel, Wason, James and Chataway, Jeremy
(2022)
Designing multi-arm multistage adaptive trials for neuroprotection in progressive multiple sclerosis.
Neurology, 98 (18).
pp. 754-764.
ISSN 0028-3878
Preview |
PDF (Accepted_Manuscript)
- Accepted Version
Available under License Creative Commons Attribution. Download (481kB) | Preview |
Abstract
There are few treatments shown to slow disability progression in progressive multiple sclerosis (PMS). One challenge has been efficiently testing the pipeline of candidate therapies from preclinical studies in clinical trials. Multi-arm multistage (MAMS) platform trials may accelerate evaluation of new therapies compared to traditional sequential clinical trials. We describe a MAMS design in PMS focusing on selection of interim and final outcome measures, sample size, and statistical considerations. The UK MS Society Expert Consortium for Progression in MS Clinical Trials reviewed recent phase II and III PMS trials to inform interim and final outcome selection and design measures. Simulations were performed to evaluate trial operating characteristics under different treatment effect, recruitment rate, and sample size assumptions. People with MS formed a patient and public involvement group and contributed to the trial design, ensuring it would meet the needs of the MS community. The proposed design evaluates 3 experimental arms compared to a common standard of care arm in 2 stages. Stage 1 (interim) outcome will be whole brain atrophy on MRI at 18 months, assessed for 123 participants per arm. Treatments with sufficient evidence for slowing brain atrophy will continue to the second stage. The stage 2 (final) outcome will be time to 6-month confirmed disability progression, based on a composite clinical score comprising the Expanded Disability Status Scale, Timed 25-Foot Walk test, and 9-Hole Peg Test. To detect a hazard ratio of 0.75 for this primary final outcome with 90% power, 600 participants per arm are required. Assuming one treatment progresses to stage 2, the trial will recruit ≈1,900 participants and last ≈6 years. This is approximately two-thirds the size and half the time of separate 2-arm phase II and III trials. The proposed MAMS trial design will substantially reduce duration and sample size compared to traditional clinical trials, accelerating discovery of effective treatments for PMS. The design was well-received by people with multiple sclerosis. The practical and statistical principles of MAMS trial design may be applicable to other neurodegenerative conditions to facilitate efficient testing of new therapies.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | clinical neurology ,/dk/atira/pure/subjectarea/asjc/2700/2728 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > School of Health Sciences |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Centres > Lifespan Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 31 Mar 2022 09:30 |
| Last Modified: | 19 Oct 2023 03:17 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/84372 |
| DOI: | 10.1212/WNL.0000000000200604 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |